ATE506966T1 - Humanisierte super-antikörper - Google Patents

Humanisierte super-antikörper

Info

Publication number
ATE506966T1
ATE506966T1 AT02752269T AT02752269T ATE506966T1 AT E506966 T1 ATE506966 T1 AT E506966T1 AT 02752269 T AT02752269 T AT 02752269T AT 02752269 T AT02752269 T AT 02752269T AT E506966 T1 ATE506966 T1 AT E506966T1
Authority
AT
Austria
Prior art keywords
humanized
antibodies
super
super antibodies
humanized super
Prior art date
Application number
AT02752269T
Other languages
English (en)
Inventor
Jefferson Foote
Original Assignee
Jefferson Foote
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jefferson Foote filed Critical Jefferson Foote
Priority claimed from PCT/US2002/022011 external-priority patent/WO2004006955A1/en
Application granted granted Critical
Publication of ATE506966T1 publication Critical patent/ATE506966T1/de

Links

AT02752269T 2002-07-12 2002-07-12 Humanisierte super-antikörper ATE506966T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/022011 WO2004006955A1 (en) 2001-07-12 2002-07-12 Super humanized antibodies

Publications (1)

Publication Number Publication Date
ATE506966T1 true ATE506966T1 (de) 2011-05-15

Family

ID=43969199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02752269T ATE506966T1 (de) 2002-07-12 2002-07-12 Humanisierte super-antikörper

Country Status (4)

Country Link
AT (1) ATE506966T1 (de)
DE (1) DE60239895D1 (de)
DK (1) DK1539233T3 (de)
ES (1) ES2370225T3 (de)

Also Published As

Publication number Publication date
DK1539233T3 (da) 2011-08-08
ES2370225T3 (es) 2011-12-13
DE60239895D1 (de) 2011-06-09

Similar Documents

Publication Publication Date Title
NO2016001I1 (no) Trastuzumab emtansin
NO20044347L (no) Anti-alfavbeta6-antistoff
CY2012019I2 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DK1599504T3 (da) Modificeret antistof
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
IS6982A (is) Mótefni gegn VLA-1
DK1501856T3 (da) Anti-HER2 antistofvarianter
IL166244A0 (en) Super humanized antibodies
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
ATE549033T1 (de) Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
NO20071430L (no) Anti-OX4OL antistoffer
IS8266A (is) Breytt mennsk IGF-1R mótefni
AU2003264009A8 (en) Humanized rabbit antibodies
DE602004022855D1 (de) Interleukin-10-antikörper
DE60334076D1 (de) Monoklonaler anti-mensch-tenascin-Antikörper
BRPI0509495A2 (pt) anticorpo humanizado
EE200300569A (et) CD44v6-spetsiifilised antikehad
AU2003277832A8 (en) Humanized tissue factor antibodies
NO20044145L (no) Assay for anti-INGAP antistoffer
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
DE112004002660D2 (de) Humaner monoklonaler Antikörper mit fettsenkender Wirkung
DE502004005390D1 (de) Verzögerungsregelkreis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1539233

Country of ref document: EP